Christopher Parker

1.0k total citations
30 papers, 665 citations indexed

About

Christopher Parker is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Christopher Parker has authored 30 papers receiving a total of 665 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Christopher Parker's work include Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). Christopher Parker is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Prostate Cancer Diagnosis and Treatment (3 papers). Christopher Parker collaborates with scholars based in United Kingdom, United States and Australia. Christopher Parker's co-authors include Fred Saad, Neal D. Shore, Ola Lindén, Walter Noordzij, Jae H. Park, Valerie Lewington, Clemens Kratochwil, Moshe Levy, Scott Caroen and David P. Dearnaley and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Christopher Parker

28 papers receiving 655 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Parker United Kingdom 12 286 214 162 127 111 30 665
Daniel Buergy Germany 13 152 0.5× 93 0.4× 289 1.8× 157 1.2× 143 1.3× 29 674
William Berry United States 8 252 0.9× 76 0.4× 226 1.4× 297 2.3× 164 1.5× 16 675
Viljem Kovač Slovenia 20 641 2.2× 122 0.6× 292 1.8× 247 1.9× 136 1.2× 69 1.0k
Nadia Pasinetti Italy 13 368 1.3× 160 0.7× 270 1.7× 133 1.0× 160 1.4× 38 809
Shuncong Wang China 16 211 0.7× 69 0.3× 349 2.2× 209 1.6× 98 0.9× 40 773
C Mossetti Italy 13 350 1.2× 79 0.4× 380 2.3× 131 1.0× 77 0.7× 31 745
Lucia Zanoni Italy 15 638 2.2× 519 2.4× 173 1.1× 77 0.6× 174 1.6× 50 1.0k
Joline S.J. Lim Singapore 14 144 0.5× 129 0.6× 392 2.4× 303 2.4× 162 1.5× 56 805
Anastasios Dimou United States 16 311 1.1× 71 0.3× 481 3.0× 201 1.6× 115 1.0× 67 800
Sasja F. Mulder Netherlands 12 340 1.2× 51 0.2× 253 1.6× 265 2.1× 130 1.2× 38 669

Countries citing papers authored by Christopher Parker

Since Specialization
Citations

This map shows the geographic impact of Christopher Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Parker more than expected).

Fields of papers citing papers by Christopher Parker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Parker. The network helps show where Christopher Parker may publish in the future.

Co-authorship network of co-authors of Christopher Parker

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Parker. A scholar is included among the top collaborators of Christopher Parker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Parker. Christopher Parker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peterse, Elisabeth F.P., et al.. (2023). Retrospective Comparison of Survival Projections for CAR T-Cell Therapies in Large B-Cell Lymphoma. PharmacoEconomics - Open. 7(6). 941–950. 1 indexed citations
2.
3.
Parker, Christopher, A Chambers, Dustin J. Flanagan, et al.. (2022). BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination. DNA repair. 115. 103331–103331. 6 indexed citations
4.
Moschini, Marco, Peter R. Carroll, Scott E. Eggener, et al.. (2017). Low-risk Prostate Cancer: Identification, Management, and Outcomes. European Urology. 72(2). 238–249. 61 indexed citations
5.
Reid, Tony, George A. Fisher, Corey Carter, et al.. (2016). Abstract B26: RRx-001, a novel epigenetic modulator: Resensitization to previously failed therapy in the ongoing phase 2 colorectal cancer study, ROCKET. Cancer Research. 76(2_Supplement). B26–B26. 1 indexed citations
6.
7.
Carter, Joanne L., Christopher Parker, Paul E. Stevens, et al.. (2016). Biological Variation of Plasma and Urinary Markers of Acute Kidney Injury in Patients with Chronic Kidney Disease. Clinical Chemistry. 62(6). 876–883. 35 indexed citations
8.
Gabram‐Mendola, Sheryl, Jean O’Connor, Roland Matthews, et al.. (2016). Hereditary breast and ovarian cancer: risk assessment in minority women and provider knowledge gaps. The Journal of Community and Supportive Oncology. 14(6). 261–267. 7 indexed citations
9.
Parker, Christopher, Gemma L. Kay, Esprit Ma, et al.. (2016). Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial.. Journal of Clinical Oncology. 34(7_suppl). 19–19. 1 indexed citations
10.
Parker, Christopher, Beth Woods, James Eaton, et al.. (2016). Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. Journal of Medical Economics. 20(1). 8–18. 7 indexed citations
11.
Oronsky, Bryan, Corey A. Carter, Jan Scicinski, et al.. (2015). The War on Cancer: A Military Perspective. Frontiers in Oncology. 4. 387–387. 15 indexed citations
12.
Scicinski, Jan, George A. Fisher, Corey Carter, et al.. (2015). The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent. Redox Biology. 5. 422–422. 15 indexed citations
13.
Oronsky, Bryan, Neil Oronsky, Gary R. Fanger, et al.. (2014). Follow the ATP: Tumor Energy Production: A Perspective. Anti-Cancer Agents in Medicinal Chemistry. 14(9). 1187–1198. 66 indexed citations
14.
Parker, Christopher, et al.. (2014). Clostridium difficile-associated disease: how much do we really know? A single institution study. 19(4). 122–127. 1 indexed citations
15.
Parker, Christopher, Steven Y. C. Tong, Karen Dempsey, et al.. (2014). Hepatocellular carcinoma in Australia's Northern Territory: high incidence and poor outcome. The Medical Journal of Australia. 201(8). 470–474. 43 indexed citations
16.
Dewilde, Sarah, et al.. (2013). Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin’s lymphoma in England and Wales. Journal of Medical Economics. 17(2). 111–124. 14 indexed citations
17.
Pezaro, Carmel, Aurelius Omlin, Amelia Altavilla, et al.. (2013). Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. European Urology. 66(3). 459–465. 122 indexed citations
18.
Parker, Christopher, Tara Haycocks, Andrew Bayley, et al.. (2002). A Dose-Volume Histogram Analysis of the Seminal Vesicles in Men Treated with Conformal Radiotherapy to ‘Prostate Alone’. Clinical Oncology. 14(4). 298–302. 5 indexed citations
19.
Brown, Bruce Alan, Christopher Parker, & Kraig S. Bower. (2001). Effective Steroid-sparing Treatment for Peripheral Ulcerative Keratitis and Pyoderma Gangrenosum. Cornea. 20(1). 117–118. 17 indexed citations
20.
Parker, Christopher & D. P. Page Thomas. (2000). Reiter's syndrome and reactive arthritis.. PubMed. 100(2). 101–4. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Buergy Breakdown of academic impact, for papers by William Berry Breakdown of academic impact, for papers by Viljem Kovač Breakdown of academic impact, for papers by Nadia Pasinetti Breakdown of academic impact, for papers by Shuncong Wang Breakdown of academic impact, for papers by C Mossetti Breakdown of academic impact, for papers by Lucia Zanoni Breakdown of academic impact, for papers by Joline S.J. Lim Breakdown of academic impact, for papers by Anastasios Dimou Breakdown of academic impact, for papers by Sasja F. Mulder
Rankless by CCL
2026